Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 4/20 | 0.49 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11342559 | 0.95 | ADAMTS5 (0.56) | ALDH1A1LMNAPPARGADAMTS5MMP2 | |
| SCHEMBL11344065 | 0.95 | ADAMTS5 (0.56) | ALDH1A1LMNAPPARGADAMTS5MMP2 | |
| SCHEMBL11351933 | 0.94 | NHERF1 (0.49) | ALDH1A1LMNAKMT2AMEN1CA2 | |
| SCHEMBL11351930 | 0.94 | NHERF1 (0.49) | ALDH1A1LMNAKMT2AMEN1CA2 | |
| SCHEMBL11352174 | 0.91 | NAMPT (0.49) | ALDH1A1LMNACA2PPARGADAMTS5 | |
| SCHEMBL28805317 | 0.86 | ALDH1A1 (0.51) | ALDH1A1LMNAKMT2AMEN1CYP2C9 | |
| SCHEMBL29855078 | 0.85 | PPARG (0.50) | ALDH1A1LMNAKMT2ACA2PPARG | |
| SCHEMBL8003721 | 0.85 | ALDH1A1 (0.54) | ALDH1A1LMNAKMT2AMEN1PPARG | |
| SCHEMBL148423 | 0.84 | FOLH1 (0.55) | ALDH1A1KMT2AMEN1CA2FOLH1 | |
| SCHEMBL8414223 | 0.84 | FOLH1 (0.55) | ALDH1A1KMT2AMEN1CA2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153365-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2012-04-10 | — | — | US | disclosed |
| US-8034909-B2 | Oligonucleotide analogues | EXIQON A/S (DK) | 2011-10-11 | — | — | US | disclosed |
| US-20110245327-A1 | Oligonucleotide Analogues | EXIQON A/S (DK) | 2011-10-06 | — | — | US | disclosed |
| EP-2341057-A2 | Oligonucleotide Analogues | Exiqon A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| EP-2341058-A2 | Oligonucleotide Analogues | Exiqon A/S (DK) | 2011-07-06 | — | — | EP | disclosed |
| US-20080227847-A1 | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use | ADITECH PHARMA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| US-6376655-B1 | APPLYING EXTERNAL STIMULATION; OPTICAL ANISOTROPY | RISO NATIONAL LABORATORY (DK) | 2002-04-23 | — | — | US | disclosed |
| EP-0031653-A1 | N-Substituted alpha-amino acids, processes for making them and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1981-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245327-A1 | Oligonucleotide Analogues | POLRMT, POLM, POLN | ALDH1A1 3811/4885LMNA 496/4885KMT2A 3747/4885 |
| US-20080227847-A1 | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use | FAH, SLC16A1, FH | ALDH1A1 320/4885LMNA 4645/4885KMT2A 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.